Trial Profile
Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Octreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms XELBEVOCT
- 25 Sep 2010 New trial record